ALS Trial Failures Knowledge Gap

Overview

This page provides a systematic analysis of why amyotrophic lateral sclerosis (ALS) clinical trials fail despite strong preclinical rationale, with recommendations for future trial designs.

Last Updated: 2026-03-13 PT

Gap Statement

Why have many neuroprotective phase II/III ALS trials failed despite strong preclinical rationale?[@van2024][@pugdahl2007]

Score: 30 (Tier 1) Rank: #9 in ALS Knowledge Gaps

Introduction

Despite over 50 clinical trial failures since the 1990s, the translation from promising preclinical results to clinical efficacy remains the central challenge in ALS drug development. This gap encompasses preclinical model limitations, species differences, trial design flaws, patient heterogeneity, and fundamental gaps in understanding disease biology.[@petrov2017]

The approval of tofersen for SOD1-associated ALS in 2023 demonstrated that careful patient selection, genetic stratification, and biomarker-driven endpoints can yield positive results. However, extending this success to broader ALS populations remains the central challenge.[@miller2022]

Summary of Key Failure Modes

Overview

This page provides a systematic analysis of why amyotrophic lateral sclerosis (ALS) clinical trials fail despite strong preclinical rationale, with recommendations for future trial designs.

Last Updated: 2026-03-13 PT

Gap Statement

Why have many neuroprotective phase II/III ALS trials failed despite strong preclinical rationale?[@van2024][@pugdahl2007]

Score: 30 (Tier 1) Rank: #9 in ALS Knowledge Gaps

Introduction

Despite over 50 clinical trial failures since the 1990s, the translation from promising preclinical results to clinical efficacy remains the central challenge in ALS drug development. This gap encompasses preclinical model limitations, species differences, trial design flaws, patient heterogeneity, and fundamental gaps in understanding disease biology.[@petrov2017]

The approval of tofersen for SOD1-associated ALS in 2023 demonstrated that careful patient selection, genetic stratification, and biomarker-driven endpoints can yield positive results. However, extending this success to broader ALS populations remains the central challenge.[@miller2022]

Summary of Key Failure Modes

| Category | Issue | Impact | Mitigation |
|---|---|---|---|
| Preclinical models | SOD1 mice don't capture sporadic ALS | High | Develop C9orf72, TDP-43, FUS models |
| Species differences | Blood-brain barrier, metabolism, physiology | High | Better PK/PD translation |
| Trial design | Endpoint selection, patient heterogeneity | High | Biomarker enrichment, composite endpoints |
| Treatment timing | Animal studies pre-symptomatic; humans post-diagnosis | Medium | Earlier intervention studies |
| Dosing | Maximum tolerated dose may not be optimal | Medium | Biomarker-guided dosing |
| Genetic stratification | Mixed ALS populations in trials | High | Genotype-specific trials |

Detailed Analysis of Failed Trial Mechanisms

1. Glutamate Excitotoxicity Targets (Historical Focus)

The majority of early ALS trials focused on glutamate excitotoxicity, reflecting the initial hypothesis that excess glutamate caused motor neuron death:

• Riluzole (1995): The only approved neuroprotective drug, showing modest survival benefit (~2-3 months)[@bensimon1994]
• Ceftriaxone (2013, Phase III): Failed to meet efficacy endpoints despite strong preclinical data[@paganoni2013]
• Mexiletine: Mixed results in Phase II

2. Oxidative Stress and Mitochondrial Dysfunction

Multiple antioxidants and mitochondrial protectors have failed:

• Idebenone (2006, Phase III): Failed primary endpoint[@liguori2013]
• CoQ10 (Phase II): Did not meet endpoints
• Mitochondrial protectors: Numerous compounds failed translation

3. Neuroinflammation Targets

Anti-inflammatory approaches have shown mixed results:

• Minocycline (2007, Phase III): Actually worsened outcomes vs placebo[@gordon2007]
• Masitinib (2019): Mixed results, not FDA approved

4. Protein Aggregation and Proteostasis

Despite TDP-43 aggregation being the hallmark pathology in >95% of ALS cases, aggregation-targeting trials have struggled:

• Arimoclomol (Phase III): Did not meet primary endpoints
• Sodium phenylbutyrate/taurursodiol (AMX0035): Mixed results

5. Growth Factors and Neurotrophic Support

• Stem cell therapies: Mixed results, delivery challenges
• CNTF, BDNF: Failed in clinical trials

Common Failure Patterns: Systematic Analysis

Pattern 1: Preclinical-to-Clinical Translation Gap

The SOD1 transgenic mouse model, while valuable, has limited translational validity:

| Characteristic | SOD1 Mouse Model | Human ALS |
|---|---|---|
| Disease trigger | Genetic overexpression | Variable (genetic/sporadic) |
| Progression timeline | Weeks to months | Years |
| Pathology | SOD1 aggregation | TDP-43 aggregation (majority) |
| Treatment window | Pre-symptomatic | Post-diagnostic |

Key Insight: Over 200 compounds showed efficacy in SOD1 mouse models but failed in human trials.[@benatar2007]

Pattern 2: Single-Pathway Targeting

ALS involves multiple simultaneous pathological processes:

Single-pathway interventions may be insufficient when multiple parallel processes drive disease.

Pattern 3: Patient Population Heterogeneity

ALS is increasingly recognized as a collection of molecularly distinct syndromes:

| Subtype | Genetic Basis | Estimated % | Implications |
|---|---|---|---|
| C9orf72 | Hexanucleotide expansion | ~40% familial, ~5-10% sporadic | Most common genetic form |
| SOD1 | Point mutations | ~15-20% familial | Target for ASO therapy |
| FUS | FUS protein mutations | ~5% familial | RNA processing focus |
| TARDBP | TDP-43 mutations | ~5% familial | Proteinopathy focus |
| Sporadic | Unknown | ~50-70% | Most heterogeneous |

Most trials have not stratified by genotype, potentially masking efficacy in specific subgroups.

Pattern 4: Endpoint Limitations

The ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised) has significant limitations:

• Subjective scoring with high inter-rater variability
• Floor effects as disease progresses
• Insufficient sensitivity to detect small but clinically meaningful changes
• Variable rate of progression affects power calculations

• Neurofilament light chain (NfL): Strong predictor of progression[@benatar2018]
• Neurofilament heavy chain (pNfH)
• CSF total tau and p-tau

Pattern 5: Treatment Timing

A fundamental mismatch exists between preclinical and clinical treatment windows:

| Study Type | Typical Treatment Start | Disease Stage |
|---|---|---|
| Mouse models | Pre-symptomatic | Pre-clinical |
| Human trials | Post-diagnostic | Established disease |

By the time patients present with symptoms, significant motor neuron loss has already occurred.

Recommendations for Future Trial Designs

1. Genetic Stratification (Priority)

Design trials for specific genotypes rather than all-comers:

• SOD1 trials: Leverage tofersen model—ASO approach validated[@miller2022]
• C9orf72 trials: Target both gain-of-function (toxic RNA) and loss-of-function
• Sporadic ALS: Develop biomarker-based subtyping approaches

2. Biomarker Integration

Implement biomarker-driven patient selection and endpoints:

| Biomarker | Use Case | Status |
|---|---|---|
| NfL | Patient enrichment, endpoint | Qualified in some contexts |
| pNfH | Progression marker | Under validation |
| CSF NfL | Pharmacodynamic marker | Emerging |
| Genetic testing | Patient stratification | Required for gene-specific trials |

3. Disease Modification Focus

Target upstream mechanisms rather than downstream symptoms:

• RNA processing modulators (validated in C9orf72, SOD1)
• TDP-43 pathway interventions (most common pathology)
• Proteostasis restoration

4. Combination Therapy Approaches

Given the multi-pathway nature of ALS, combination strategies may be necessary:

• Example: Anti-aggregation + anti-inflammatory + metabolic support
• Challenge: Regulatory complexity of combination trials
• Opportunity: Platform trials with multiple arms

5. Earlier Intervention

• Pre-symptomatic carriers: Design prevention trials for genetic carriers
• Prodromal markers: Develop conversion prediction models
• At-risk populations: Consider exposure-linked risk modeling

6. Adaptive Trial Designs

Implement more efficient trial architectures:

• Platform trials: Master protocols with multiple treatments
• Bayesian adaptive designs: More flexible endpoint analysis
• Seamless Phase II/III: Accelerated development

Investment and Company Landscape

The ALS investment landscape reflects both the challenges and opportunities in the field:

Key Players in ALS Drug Development

| Company | Approach | Status |
|---|---|---|
| Biogen / Ionis | SOD1 ASO (tofersen) | Approved |
| Wave Life Sciences | C9orf72 ASO | In development |
| Denali Therapeutics | Small molecules, transport technology | Multiple programs |
| Prevail Therapeutics | Gene therapy | Acquired by Eli Lilly |

Investment Metrics

For detailed investment data, see the ALS Investment Landscape page, which tracks:

• 1,568 total tracked trials (as of March 2026)
• 454 active trials (29%)
• 140 late-stage trials (Phase 3/4, 8.9%)
• 124 biomarker-forward programs (7.9%)

Underrepresented Mechanism Areas

Based on portfolio analysis, the following mechanisms are underinvested relative to their biological importance:

• TDP-43 biology: Primary pathology in most ALS cases
• Neuroinflammation: Modulation vs suppression
• Non-cell-autonomous pathways: Glial involvement
• Metabolic dysfunction: Energy metabolism in neurodegeneration

Cross-Links to Related Content

Disease and Mechanism Pages

• [ALS disease overview](/diseases/amyotrophic-lateral-sclerosis) — Primary disease page
• [ALS Knowledge Gaps](/gaps/als) — Parent gap page with ranked priorities
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — Primary pathology in most ALS
• [ALS pathway](/mechanisms/als-pathway) — Disease mechanism overview
• [ALS RNA metabolism and proteostasis failure](/mechanisms/als-rna-metabolism)
• [ALS biomarkers and disease monitoring](/biomarkers/als-biomarkers)
• [Non-cell-autonomous glial pathways in ALS](/mechanisms/als-glial-pathways)

Treatment Pages

• [Tofersen](/therapeutics/tofersen) — Success case study
• [ALS therapeutics](/treatments/als-therapeutics) — Treatment pipeline overview

Investment and Company Pages

• [ALS Investment Landscape](/investment/als-investment-landscape) — R&D investment analysis
• [ALS vs FTD: Comparative Investment Analysis](/investment/als-ftd-comparison)
• [Biogen](/companies/biogen) — Tofersen developer
• [Ionis Pharmaceuticals](/companies/ionis-pharmaceuticals) — ASO technology partner
• [Denali Therapeutics](/companies/denali-therapeutics) — Multiple ALS programs
• [Prevail Therapeutics](/companies/prevail-therapeutics) — Gene therapy approaches

Clinical Trial Resources

• [Clinical Trials Index](/clinical-trials) — Searchable trial database
• [Promising clinical trials in neurodegeneration](/clinical-trials/drug-pipeline)

Lessons from Tofersen: A Success Model

Tofersen (Qalsody) demonstrates that carefully designed trials can succeed:

| Factor | Tofersen Approach | Implication for Future Trials |
|---|---|---|
| Genetic stratification | SOD1 mutation carriers only | Genotype-specific enrollment |
| Biomarker endpoints | NfL reduction as pharmacodynamic marker | Early biological activity |
| Target engagement | Direct ASO delivery to CSF | Ensure target access |
| Extended follow-up | Open-label extension allowed long-term assessment | Capture delayed effects |

Key Learnings:

• Molecular confirmation of target engagement is achievable
• Neurofilament reduction correlates with clinical outcomes
• Early treatment may provide greater benefit[@miller2022]

See Also

• [ALS Knowledge Gaps — Parent gap page](/content/gaps)
• [Knowledge Gaps Index](/content/gaps)
• [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons)
• [FTD Knowledge Gaps](/content/gaps)
• [Tauopathies Knowledge Gaps](/content/gaps)
• [Alzheimer's Disease Knowledge Gaps](/gaps/alzheimers-disease)

Pathway Diagram

The following diagram shows the key molecular relationships involving ALS Trial Failures Knowledge Gap discovered through SciDEX knowledge graph analysis: